Peter Clark to Prognosis
This is a "connection" page, showing publications Peter Clark has written about Prognosis.
Connection Strength
1.000
-
Balci M, Glaser ZA, Chang SS, Herrell SD, Barocas DA, Keegan KA, Moses KA, Resnick MJ, Smith JA, Penson DF, Scarpato K, Clark PE. Differential effect of body mass index by gender on oncological outcomes in patients with renal cell carcinoma. J Cancer Res Ther. 2021 Apr-Jun; 17(2):420-425.
Score: 0.139
-
Lipworth L, Morgans AK, Edwards TL, Barocas DA, Chang SS, Herrell SD, Penson DF, Resnick MJ, Smith JA, Clark PE. Renal cell cancer histological subtype distribution differs by race and sex. BJU Int. 2016 Feb; 117(2):260-5.
Score: 0.093
-
Kaffenberger SD, Morgan TM, Stratton KL, Boachie AM, Barocas DA, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE. ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. BJU Int. 2012 Dec; 110(11 Pt B):E641-6.
Score: 0.077
-
Boudreaux KJ, Chang SS, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA, Clark PE. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Cancer. 2009 Feb 15; 115(4):770-5.
Score: 0.060
-
Clark PE. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma. Eur Urol. 2009 Jun; 55(6):1343-4.
Score: 0.060
-
Coons BJ, Stec AA, Stratton KL, Chang SS, Cookson MS, Duke Herrell S, Smith JA, Clark PE. Prognostic factors in T3b renal cell carcinoma. World J Urol. 2009 Feb; 27(1):75-9.
Score: 0.059
-
Barocas DA, Clark PE. Bladder cancer. Curr Opin Oncol. 2008 May; 20(3):307-14.
Score: 0.057
-
Heilbrun ME, Zagoria RJ, Garvin AJ, Hall MC, Krehbiel K, Southwick A, Clark PE. CT-guided biopsy for the diagnosis of renal tumors before treatment with percutaneous ablation. AJR Am J Roentgenol. 2007 Jun; 188(6):1500-5.
Score: 0.053
-
Clark PE, Veys JA, Eskridge MR, Woodruff RD, Hall MC. Prognostic significance of clinicopathologic and deoxyribonucleic acid flow cytometric variables in non-metastatic renal cell carcinoma in the modern era. Urol Oncol. 2005 Sep-Oct; 23(5):328-32.
Score: 0.047
-
Burgess EF, Livasy C, Trufan S, Hartman A, Guerreri R, Naso C, Clark PE, Grigg C, Symanowski J, Raghavan D. High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy. Urol Oncol. 2019 12; 37(12):900-906.
Score: 0.031
-
David SN, Arnold Egloff SA, Goyal R, Clark PE, Phillips S, Gellert LL, Hameed O, Giannico GA. MAGI2 is an independent predictor of biochemical recurrence in prostate cancer. Prostate. 2018 06; 78(8):616-622.
Score: 0.028
-
Arnold Egloff SA, Du L, Loomans HA, Starchenko A, Su PF, Ketova T, Knoll PB, Wang J, Haddad AQ, Fadare O, Cates JM, Lotan Y, Shyr Y, Clark PE, Zijlstra A. Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. Oncotarget. 2017 Jan 03; 8(1):722-741.
Score: 0.026
-
Arnold SA, Loomans HA, Ketova T, Andl CD, Clark PE, Zijlstra A. Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer. Clin Exp Metastasis. 2016 Jan; 33(1):29-44.
Score: 0.024
-
Reddy OL, Cates JM, Gellert LL, Crist HS, Yang Z, Yamashita H, Taylor JA, Smith JA, Chang SS, Cookson MS, You C, Barocas DA, Grabowska MM, Ye F, Wu XR, Yi Y, Matusik RJ, Kaestner KH, Clark PE, DeGraff DJ. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. Am J Pathol. 2015 May; 185(5):1385-95.
Score: 0.023
-
Morgan TM, Barocas DA, Keegan KA, Cookson MS, Chang SS, Ni S, Clark PE, Smith JA, Penson DF. Volume outcomes of cystectomy--is it the surgeon or the setting? J Urol. 2012 Dec; 188(6):2139-44.
Score: 0.019
-
Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol. 2013 Jan; 63(1):4-15.
Score: 0.019
-
Morgan TM, Barocas DA, Penson DF, Chang SS, Ni S, Clark PE, Smith JA, Cookson MS. Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. Urology. 2012 Sep; 80(3):632-40.
Score: 0.019
-
Morgan TM, Keegan KA, Barocas DA, Ruhotina N, Phillips SE, Chang SS, Penson DF, Clark PE, Smith JA, Cookson MS. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol. 2011 Sep; 186(3):829-34.
Score: 0.018
-
Anderson CB, Clark PE, Morgan TM, Stratton KL, Herrell SD, Davis R, Cookson MS, Smith JA, Chang SS. Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. Urology. 2011 Jul; 78(1):99-104.
Score: 0.018
-
Thompson IM, Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Baumgartner R, Phillips S, Smith JA, Cookson MS, Barocas DA. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods. World J Urol. 2011 Feb; 29(1):15-20.
Score: 0.017
-
Newton MR, Phillips S, Chang SS, Clark PE, Cookson MS, Davis R, Fowke JH, Herrell SD, Baumgartner R, Chan R, Mishra V, Blume JD, Smith JA, Barocas DA. Smaller prostate size predicts high grade prostate cancer at final pathology. J Urol. 2010 Sep; 184(3):930-7.
Score: 0.017
-
Stimson CJ, Cookson MS, Barocas DA, Clark PE, Humphrey JE, Patel SG, Smith JA, Chang SS. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol. 2010 May; 183(5):1732-7.
Score: 0.016
-
Kordan Y, Chang SS, Salem S, Cookson MS, Clark PE, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA, Barocas DA. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. J Urol. 2009 Nov; 182(5):2291-5.
Score: 0.016
-
Barocas DA, Patel SG, Chang SS, Clark PE, Smith JA, Cookson MS. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. BJU Int. 2009 Oct; 104(8):1091-7.
Score: 0.015
-
Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, Smith JA, Clark PE, Bhowmick NA. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res. 2008 Dec 01; 14(23):7790-7.
Score: 0.015
-
Gwynn ES, Clark PE, Hall MC. Recent advances in the treatment of bladder cancer. Expert Rev Anticancer Ther. 2005 Dec; 5(6):1023-30.
Score: 0.012
-
Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 2003 Sep 01; 98(5):955-61.
Score: 0.010
-
Borden LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2003 May; 15(3):227-33.
Score: 0.010